Empowering itself

After raising E40 million ($51.3 million) in a series C round last August, Ablynx N.V. CEO Edwin Moses said the next-generation antibody company would shift away from deals under which it provided Nanobodies against partners' targets toward deals where Ablynx would have greater control over target choice and development. A collaboration

Read the full 518 word article

How to gain access

Continue reading with a
two-week free trial.